This is a $1,405,000.00 firm fixed price purchase order contract awarded by the National Human Genome Research Institute, a component of the Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for services related to beta cell differentiation and cell assays, which aligns with the original solicitation that sought the development of assays to evaluate the differentiation of stem cells into insulin-producing beta cells. No set-aside designation was used for this award. The contract has a period of performance through June 23, 2025. The New York Stem Cell Foundation Inc. has previously performed similar work for the National Institutes of Health, including generating induced pluripotent stem cell lines, differentiating stem cells, and expanding and validating neural progenitor cells.